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Abstract
Therapeutic inhibition of poly(ADP-ribose) polymerase (PARP), as monotherapy or to sup-
plement the potencies of other agents, is a promising strategy in cancer treatment. We pre-
viously reported that the first PARP inhibitor to enter clinical trial, rucaparib (AG014699),
induced vasodilation in vivo in xenografts, potentiating response to temozolomide. We now
report that rucaparib inhibits the activity of the muscle contraction mediator myosin light
chain kinase (MLCK) 10-fold more potently than its commercially available inhibitor ML-9.
Moreover, rucaparib produces additive relaxation above the maximal degree achievable
with ML-9, suggesting that MLCK inhibition is not solely responsible for dilation. Inhibition of
nitric oxide synthesis using L-NMMA also failed to impact rucaparib’s activity. Rucaparib
contains the nicotinamide pharmacophore, suggesting it may inhibit other NAD+-dependent
processes. NAD+ exerts P2 purinergic receptor-dependent inhibition of smooth muscle con-
traction. Indiscriminate blockade of the P2 purinergic receptors with suramin abrogated
rucaparib-induced vasodilation in rat arterial tissue without affecting ML-9-evoked dilation,
although the specific receptor subtypes responsible have not been unequivocally identified.
Furthermore, dorsal window chamber and real time tumor vessel perfusion analyses in
PARP-1-/- mice indicate a potential role for PARP in dilation of tumor-recruited vessels. Fi-
nally, rucaparib provoked relaxation in 70% of patient-derived tumor-associated vessels.
These data provide tantalising evidence of the complexity of the mechanism underlying
rucaparib-mediated vasodilation.
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Introduction
Poly (ADP-ribose) polymerase -1 and -2 (PARP-1 and -2) are DNA damage-activated enzymes
that participate in multiple DNA repair pathways, including base excision repair [1,2]. Upon
binding to DNA breaks, PARP-1/2 ADP-ribosylate themselves, histones H1 and H2B, loosen-
ing chromatin and facilitating repair, concomitantly consuming NAD+ and releasing nicotin-
amide [1,2]. PARP-1 or -2 loss or inhibition results in increased sensitivity to DNA alkylating
agents, topoisomerase I poisons and ionizing radiation. Attention is now being paid to PARP
inhibitors as cancer chemosensitisers [3].
AG14361 (one of a series of tricyclic benzimidazole carboxamide PARP inhibitors [4] is a
potent chemo- and radiosensitizer in vitro and in vivo [5] and inhibits the repair of double
strand breaks in DNA, sensitizing cancer cells to ionising radiation [6]. Further development
of this series of inhibitors identified AG14447 as a chemosensitizer with ten times the potency
of AG14361; the phosphate salt of AG14447 is AG014699, now called rucaparib, which has
equivalent potency and improved pharmacological properties [7]. Rucaparib was the first
PARP inhibitor tested in cancer patients. Rucaparib displayed encouraging activity in phase I
and phase II trials for treatment of metastatic malignant melanoma in combination with temo-
zolomide [8]. There are now several PARP inhibitors in advanced clinical trials, including
BMN-673, olaparib, veliparib and niraparib, as well as rucaparib (www.clinicaltrials.gov).
In SW620 xenografts, AG14361 was a more potent chemosensitizer than it was during in
vitro testing; visualization of the tumor vasculature indicated that this anomaly may be attrib-
utable to effects of the drug on tumor blood flow [5]. Rucaparib, like most PARP inhibitors,
contains the nicotinamide pharmacophore. Nicotinamide (itself a weak PARP inhibitor) was
demonstrated to enhance radiotherapy by increasing tumor perfusion over two decades ago
[9]. However, its therapeutic benefit is restricted by its dose-limiting toxicity, emesis, which has
been attributed to inhibition of contraction of smooth muscle of the gut, resultant of myosin
light chain kinase (MLCK) inhibition [10]. We showed previously that both rucaparib and
AG14361 induced relaxation of constricted rat arteries, but only rucaparib inhibited MLCK ac-
tivity [11]. It is evident that a mechanism more complex than MLCK inhibition is responsible
for vasodilation induced by these PARP inhibitors.
The purpose of the current study was to gain a better understanding of the behavior of ruca-
parib by delineating the mechanism of its vasoactivity using rat arterial tissue and tumor-re-
cruited vascular tissue in wild-type and PARP-1-/- mice. Additionally, we investigated whether
freshly excised tumor-associated vascular tissue from patients having undergone nephrectomy
for renal cell carcinoma displayed a similar pattern of response to rucaparib. Our results indi-
cate that rucaparib-evoked relaxation of arterial tissue is reliant on MLCK inhibition, is depen-
dent on P2 purinergic receptors, and may involve PARP itself.
Materials and Methods
Chemicals and reagents
All chemicals and reagents were from Sigma, Dorset, UK unless otherwise stated. Rucaparib
was kindly provided by Pfizer GRD (La Jolla, USA).
Animals
All animal experiments were carried out in accordance with the Animal (Scientific Procedures)
Act 1986 and conformed to the current UKCCCR guidelines. Rat tissue experiments were ap-
proved by the Home Office Inspectorate and by the Animal Welfare and Ethics Review Body at
Queen’s University, Belfast. Mouse experiments were approved by the Home Office
Vasoactivity of PARP Inhibitor Rucaparib
PLOS ONE | DOI:10.1371/journal.pone.0118187 February 17, 2015 2 / 16
research grant from Agouron/Pfizer, and both NJC
and KJW are named inventors on the following
patents relating to rucaparib: Calvert AH, Curtin NJ,
Jones C, Newell DR, Plummer ER and Thomas HR.
Therapeutic Combinations Comprising PARP inhibitor
US application No. 60/612,458 Filed 22nd September
2004 WO/2006/033006) THERAPEUTIC
COMBINATIONS COMPRISING POLY
(ADPRIBOSE) POLYMERASES INHIBITOR
Helleday T and Curtin NJ. Therapeutic Compounds
(PARP inhibitors in homologous repair/BRCA
defective cancer) Patent Application Number PCT/
GB2004/003183. Publication number WO 2005/
012305 A2 Divisional application 16th April 2004 GB
0408524.7. There are no further patents, products in
development or marketed products to declare. This
does not alter the authors’ adherence to all the PLOS
ONE policies on sharing data and materials.
Inspectorate, and the Local Ethical Review Process of The University of Manchester and the In-
stitutional Animal Welfare Committee at Newcastle University. All experiments performed
complied with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines; for
S1 ARRIVE Guidelines Checklist, please see Supporting Information.
Mice were bred in-house and maintained using the highest possible standard of care, and
priority was given to their welfare. Any mice identified to be suffering were immediately sacri-
ficed. Rats were purchased from Harlan (UK). Anesthesia of mice was by isoflurane. All ani-
mals were sacrificed by CO2 asphyxiation.
Rat tail artery preparation
Tissue preparation was as previously reported [11]. Briefly, male albino Wistar rats (6–12
weeks old) were killed by CO2-asphyxiation, and death confirmed by cervical dislocation. The
tail was removed from the animal at its most proximal point. The tail artery on the ventral side
was identified in the vascular bed, was bathed in ice-cold Krebs’ solution (118 mMNaCl, 4.7
mM KCl, 25 mM NaHCO3, 1.15 mMNaH2PO4, 2.5 mM CaCl2, 1.1 mMMgCl2, 5.6 mM glu-
cose), and a 2 cm long cannula (1 mm in diameter) was introduced into the artery, and the ar-
tery slid over it until an insertion overlap of approximately 5 mm was achieved. The artery was
secured to the cannula using double-knotted thread. A length of artery approximately 10 mm
beyond the end of the cannula was freed from its vascular bed and cut.
The cannulated artery was connected to an internal/external perfusion apparatus and per-
fused with oxygenated Krebs’ (95% O2/5% CO2, BOC, Manchester, UK) at 37°C, slowly at first
(0.25 ml/min), increasing to a maximum of 2 ml/min. The artery segments were then allowed
to equilibrate for 1 h, before responsiveness was confirmed by constriction with 10 μM phenyl-
ephrine (PE).
Arterial constriction or dilation was detected as an increase or decrease in pressure detected
by transducers (monitored by water displacement) connected to a MacLab system (AD Instru-
ments Pty Ltd., Australia).
Rat aorta preparation
The rats used and method of sacrifice were as above. The aorta was removed, fibroadipose tis-
sue was discarded, and the explanted aorta placed in fresh ice-cold oxygenated Krebs’ solution.
The aorta was cut into rings 2–3 mm thick, and rings were placed on to the pins of an isometric
force transducer and lowered into a tissue bath containing Krebs’ at 37°C, with Krebs’ flowing
through at a rate of 2 ml per minute. In this system, one pin is stationary, while the second pin
is free to move vertically and is used to apply tension to the piece of tissue. Tension was gradu-
ally applied to the aortic ring until a preload of approximately 0.5 g was reached. Constriction
of the aortic ring was produced by perfusing the organ bath with 10 μM PE. Aortic constriction
or relaxation was detected by an increase or decrease in force detected by the transducers con-
nected to a MacLab system (AD Instruments Pty Ltd., Australia).
Pharmacological assessment of rucaparib
Arterial tissues were constricted using 10 μM PE. Following this, the tissues were exposed to
perfusate that contained 10 μM PE and the relevant concentration of rucaparib (Pfizer GRD,
La Jolla, California), which in most cases was in the 10 ρM to 100 μM range. The degree of re-
laxation elicited by rucaparib treatment was expressed as a percentage of the magnitude of con-
striction that was observed following 10 μM PE treatment.
The role of nitric oxide (NO_) in rucaparib-evoked vasodilation was assessed by pre-treating
arterial segments from both sites with increasing concentrations (10 nM—100 μM) of the nitric
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oxide synthase (NOS) inhibitor Nω-methyl-L-arginine acetate salt (L-NMMA) before challenge
with a combination of the relevant concentration of L-NMMA plus 100 μM rucaparib. The
presence of an intact endothelium was demonstrated by acetylcholine-evoked relaxation of PE-
constricted artery tissues.
To investigate the effects of direct inhibition of MLCK on arterial smooth muscle contrac-
tion, tissue segments were constricted using 10 μM PE as previously described, before being
treated with a combination of PE and a range of concentrations of ML-9 (a potent MLCK in-
hibitor), and a concentration response curve was constructed. The maximally-relaxant concen-
tration of ML-9 was then used in combination with 100 μM rucaparib and the degree of
relaxation was expressed as a percentage of the magnitude of constriction that was observed
following 10 μM PE treatment. Significance of differences between treatments was assessed
using Student’s t-test.
P2 receptor involvement in rucaparib-evoked dilation was determined by succeeding the
initial 10 μM PE with perfusate containing 10 μM PE plus suramin (100 pM—10 μM), perfus-
ing for 20 min to allow equilibration, before perfusing with PE, suramin and 100 μM or 500 μM
rucaparib (tail artery and aorta respectively). These protocols were duplicated to address the in-
volvement of P2 receptors in nicotinamide- and ML-9-evoked dilation. Specific P2 receptors
were antagonised using oxidised ATP (P2X7; 100 μM) Brilliant Blue G (P2X4, P2X7; 1 μM) and
MRS-2179 (P2Y1; 10 μM).
Measurement of the potency of rucaparib’s inhibition of MLCK
Kinase activity analysis was performed as reported previously, using the Millipore IC50 Profiler
Express service [11]. To determine the relative potency of rucaparib, ML-9 was incorporated
into the assay. 5 mM samples of rucaparib and ML-9 were supplied to the Drug Discovery Ser-
vice department at Millipore (Dundee, Scotland). 10-point, ½ logarithmic dilution series were
generated, and MLCK phosphorylation of the peptide substrate (KKLNRTLSFAEPG) was ana-
lysed in duplicate. The relative activity of MLCK following treatment with the relevant agent
was then expressed as a percentage of the activity of the kinase in control (1% (v/v) DMSO).
Role of PARP in vasoactivity of rucaparib
These studies were undertaken to determine the responsibility of PARP-1 in rucaparib’s vaso-
activity, and to determine whether rucaparib impacts the tone of mouse microvessels in vivo as
it does rat macrovessels ex vivo. Vessel mismatch studies were used as an ex vivomodel of
tumor vessel perfusion as previously described [11]. PARP-1-/- mice (C57BL/6 background
strain) were obtained from the de Murcia group [12], and were maintained in Newcastle for
more than 10 generations. Mice used in vessel mismatch and dorsal window chamber experi-
ments were 8–10 weeks old. Wild-type (WT) mice were not littermates of the PARP-1-/- mice,
but rather products of a WT C57BL/6 colony.
For vessel mismatch assessment, once B16 (European Collection of Cell Cultures) tumors
grown subcutaneously on the flank of C57BL/6 WT or PARP-1-/- mice achieved a diameter of
10 mm, rucaparib (1 mg/kg—a concentration sufficient to sensitize to temozolomide [11]) was
administered i.p, followed 30 min later by Hoechst 33342 (i.v., 15 mg/kg, dissolved in PBS) and
a further 20 min later by carbocyanine (i.v., 1 mg/kg, dissolved in 75% dimethyl sulphoxide). 5
min following carbocyanine delivery, mice were sacrificed, tumors were excised and rapidly
frozen. We previously reported that plasma levels of rucaparib were undetectable 4 h post-ad-
ministration of rucaparib to Capan-1 tumor-bearing mice, while intratumoral levels persisted
for 48 h, and PARP-1 inhibition persisted for 7 days [13]. Owing to rucaparib’s rapid de-
livery and prolonged activity, we chose to analyze vessel perfusion shortly following
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administration. A Nikon Eclipse E800 microscope was used to analyze the Hoechst 33342 and
carbocyanine (excitation wavelengths, 340–380 nm and 450–490 nm; emission wavelengths,
480 nm and 510 nm, for Hoechst and carbocyanine, respectively) content of vessels in 10 μm
tumor sections.
Real time dorsal window chamber analysis of tumor vessel perfusion was as previously de-
scribed [14]. Briefly, chambers implanted in C57BL/6 WT or PARP-1-/- mice were inoculated
with 30 μl of B16 cells at 5x107/ml. When tumors were established, intravital microscopy was
used to assess vascular parameters in anesthetized mice. Images were captured in both bright
field and fluorescence before and after administration of rucaparib (ip 1 mg/kg) using a Nikon
Eclipse E800. Real time tumor perfusion was assessed by quantification of the accumulation of
BSA labeled with Alexa-Fluoro-647 (BSA-647; excitation wavelength 647 nm, 1 mg/mL in ster-
ile saline; Molecular Probes; Invitrogen) that was delivered i.v. (100 μl/mouse) before rucaparib
treatment. A Metamorph analysis system was used to quantify fluorescence emission at 668
nm. Significance of differences between treatments was assessed using Student’s t-test.
Provision of human tumor-associated vascular tissue
Suitable patients who had been diagnosed with renal cell carcinoma, and for whom surgical re-
moval of the diseased tissue was deemed necessary, were identified by the urological surgical
team (P.K., N.R., C.H.). Written informed consent for human tissue procurement was obtained
from all participants following their consenting to the surgical procedure; information sheets
documenting the proposed use of tissues was provided by the urological team during a clinical
consultation. Ethical approval for the study was provided by The Office for Research Ethics
Committees Northern Ireland (ORECNI; 07/NIR02/102). Once adequate tissue was obtained
for histological diagnosis and staging of the tumor, tumor-associated vascular tissue was identi-
fied and removed from the specimen by the consultant pathologist (D.O’R.) and placed in ice-
cold Krebs’ as previously reported [15]. Following this, pharmacological characterization of
rucaparib was performed as for rat aorta. Two segments of artery were assayed per patient,
with one exception; in the case of one patient’s tissue, one tissue segment was constricted using
PE as normal, and rucaparib effects were determined; the second segment contracted sponta-
neously in an oscillatory manner, meaning constriction with PE was unnecessary; in this in-
stance, the impact of rucaparib on the magnitude of these oscillatory constrictions was
assessed. For this patient, only a single concentration of rucaparib was investigated (100 μM).
Results
Pharmacological assessment of rucaparib
PE (10 μM) consistently evoked sub-maximally attainable constrictions in both tail artery and
aortic sections. 10 μM PE constricts both rat arterial tissues to approximately 50% of what is
achievable. This level of constriction allows for characterization of the effects of agents on vas-
cular tone, either dilatory or constrictory. Although constrictions evoked by 10 μM PE are
below the maximal degree achievable, they were assigned a value of 100%, and subsequent
changes in vessel tone were expressed relative to 10 μM PE.
Rucaparib concentration-dependently inhibited PE-induced constriction in rat tail artery
segments (Fig. 1A; EC50 23.7 μM). The MLCK inhibitor ML-9 elicited dilation with an EC50 of
20.1 μM, while the EC50 for nicotinamide was 23.7 mM. PE-constricted rat aorta also relaxed
in response to rucaparib (Fig. 1B; EC50 523 μM), ML-9 (EC50 28 μM) and nicotinamide (EC50
7.8 mM).
NO_ is a potent vasodilator. To address whether rucaparib-evoked dilation was dependent
on generation of NO_, artery sections were pre-perfused with the NO_synthase (NOS) inhibitor,
Vasoactivity of PARP Inhibitor Rucaparib
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L-NMMA before challenge with rucaparib. Pre-perfusion of tail artery segments with L-
NMMA had no significant effect on rucaparib-evoked dilation except at 100 μM, when it atten-
uated the rucaparib response from 68.84 ± 1.7% to 43.52 ± 4.98% relative dilation in tail artery
(p<0.001) (S1A Fig.). L-NMMA did not significantly affect rucaparib-evoked dilation of aorta
at any concentration tested (S1B Fig.). Acetylcholine (10 μM) elicited relaxation of PE-con-
stricted tail artery and aorta segments (25.87 ± 3.3% and 14.86 ± 2.89% respectively), indicating
endothelium (NO_’s site of vasodilation induction) was intact (not shown).
Potency of rucaparib-evoked inhibition of MLCK
In both arterial models, ML-9 relaxed tissues after PE constriction. Relaxation of PE-con-
stricted segments with the maximally-relaxing concentration of ML-9 (100 μM in tail artery
Fig 1. Rucaparib-mediated vasodilation of rat vascular tissue may be partially dependent onmyosin light chain kinase. Panel A; rucaparib (closed
squares), nicotinamide (open squares) and ML-9 (open triangles) inhibit smooth muscle contraction in PE-constricted rat tail artery. Artery sections were
constricted using 10 μMPE before perfusion with a solution containing 10 μMPE plus the relevant concentration of drug. Panel B; rucaparib, nicotinamide
and ML-9 inhibit smooth muscle contraction in PE-constricted rat aorta. Panel C; inhibition of arterial smooth muscle contraction by rucaparib is dependent on
a mechanism in addition to MLCK inhibition. Constricted vessel segments were relaxed to the maximal degree achievable with ML-9, before being
challenged with a relaxing cocktail of ML-9 plus rucaparib. The histograms illustrate the additive effects that were observed in the cases of both tail artery
(left) and aorta (right). ** p<0.01, *** p<0.001 versus relaxation evoked by rucaparib alone; ΔΔ p<0.01 versus ML-9 alone. Bars represent mean of at least
three independent experiments. Arteries from at least three rats were used per test. Error bars represent SEM. Panel D; rucaparib (closed squares) inhibits
MLCK activity with ten times the potency of ML-9 (open triangles). Kinase activity was analyzed using the Millipore IC50 Profiler Express service. Points
represent results of duplicate experiments. Error bars represent SEM.
doi:10.1371/journal.pone.0118187.g001
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and 200 μM in aorta) followed by a combination of this concentration of ML-9 with 100 μM
rucaparib resulted in additional relaxation of the arterial segments, returning the tone of the
vessels to basal levels (Fig. 1C). In each case, dilation with a combination of the maximally ac-
tive concentration of ML-9 plus 100 μM rucaparib was significantly greater than dilation elic-
ited by 100 μM rucaparib alone (p = 0.009 in tail artery; p<0.001 in aorta). These data indicate
that MLCK inhibition is not solely responsible for rucaparib’s vasoactivity.
In our previous study, we demonstrated that rucaparib inhibited the activity of MLCK in an
in vitro assay [11]. The purpose of this experiment was to determine the potency of rucaparib
relative to that of ML-9, a commercially available MLCK inhibitor. Although neither inhibitor
evoked maximal inhibition of MLCK in the concentration range tested (10 nM—100 μM),
rucaparib was ten times more potent an inhibitor of MLCK activity than ML-9 (IC50s of 55 μM
[11] and 560 μM respectively; Fig. 1D).
Determination of P2 receptor involvement in rucaparib-evoked
relaxation
P2 receptors have been implicated in maintenance of vascular tone [16]. They are responsible
for ATP-induced actions [17], and are either ATP-gated ion channels (P2X) or G-protein-cou-
pled (P2Y) [18] receptor types. The agonists of these nucleotide receptors are ATP, ADP, UTP,
UDP and NAD+. β-NAD+ was recently revealed to inhibit contraction of murine smooth mus-
cle by its action at the P2Y1 receptor [19]. This, coupled with structural similarity of rucaparib
to NAD+ led us to investigate the role of P2 receptors in rucaparib-evoked vasodilation.
Perfusion of PE-constricted rat tail artery and aorta sections with suramin (P2 receptor an-
tagonist; 100 pM—10 μM) concentration-dependently abrogated rucaparib-dependent relaxa-
tion (Fig. 2A). Suramin itself was devoid of any vasoactivity in both models (Fig. 2B). Suramin
is not a universal inhibitor of smooth muscle relaxation, demonstrable by its inability to pre-
vent relaxation evoked by ML-9 in either arterial model. In the tail artery model, suramin ex-
erted a slight inhibition of nicotinamide-evoked dilation, but was without effect in the aorta
model (Fig. 2C). As above (Fig. 2A), suramin potently blocked the effects of rucaparib in both
arterial models.
Antagonism of specific P2 receptor subtypes P2X4, P2X7 and P2Y1 was unable to categori-
cally identify the receptor responsible for the activity of rucaparib in arterial tissue. Antagonism
of P2X4 with Brilliant Blue G in tail artery significantly lessened relaxation, although was with-
out effect in aortic tissue (Fig. 3A and B). Neither P2X7 nor P2Y1 antagonism with oxidised
ATP or MRS-2179 respectively affected the degree of relaxation elicited by rucaparib. Never-
theless, while the degree of relaxation achieved remained largely unchanged, Brilliant Blue G,
oxidised ATP and MRS-2179 all significantly delayed the completion of rucaparib-evoked re-
laxation (determined as stable tone that did not vary (positively or negatively) for a duration of
20 s), compared with unobstructed relaxation (Fig. 3C and D).
Role of PARP in rucaparib-mediated vasodilation
A role for PARP itself in rucaparib’s vasoactivity was investigated using tumor vessel perfusion
mismatch and dorsal window chamber analyses in C57BL/6 WT and PARP-1-/- mice. Vessel
mismatch studies work on the basis that, after venous delivery of two fluorescent dyes with an
interval of 20 minutes between, vessels that are positive for both dyes are deemed to be
‘matched’, while those vessels that are positive for either dye alone are ‘mismatched’, a phe-
nomenon that occurs by vessel opening or closing before or after fluorescent dye delivery. In
WT mice treated with saline, 40.5 ± 7.14% of vessels were mismatched, while those treated
with rucaparib had 17.1 ± 9.26% mismatched vessels (p = 0.026). Conversely, rucaparib
Vasoactivity of PARP Inhibitor Rucaparib
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Fig 2. P2 receptor blockade abrogates rucaparib-evoked vasodilation. Panel A; broad-spectrum antagonism of P2 receptors using suramin (inverted
open triangles) abrogated rucaparib-evoked relaxation in rat tail artery (left) and aorta (right). Panel B; suramin itself was without vasoactivity, demonstrable
by its failure to alter the tone of sub-maximally constricted vessels. The shaded region represents the degree of constriction evoked using 10 μMPE alone.
Panel C; suramin has little effect on vasodilation elicited by nicotinamide and none on vasodilation elicited by ML-9, but inhibits that elicited by rucaparib in tail
artery and aorta. **p<0.01, ***p<0.001 as compared with dilation achieved in the absence of suramin. Arteries from at least three rats were used per test.
doi:10.1371/journal.pone.0118187.g002
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Fig 3. Rucaparib may act at multiple P2 receptor subtypes. Panels A and B; blockade of specific P2 receptor subtypes P2X4, P2X7 and P2Y1 in tail artery
(A) and aorta (B) models failed to categorically identify the receptor subtype at which rucaparib elicits its dilatory effect. Δ p<0.05 as compared with the
degree of dilation achieved by rucaparib in the absence of P2 antagonism. Panel C; summary of the duration of perfusion of tail artery segments necessary
for relaxation plateau to be reached. Although the absolute degree of relaxation achieved was similar in the absence and presence of specific P2 receptor
Vasoactivity of PARP Inhibitor Rucaparib
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treatment did not affect the degree of vessel mismatch in PARP-1-/- mice; vessel mismatch in
saline-treated mice was 40.3 ± 18.8%, while in rucaparib-treated mice, vessel mismatch was
50.9 ± 18.9% (p = 0.53; Fig. 4A and B), indicating that the PARP inhibitor lacked potency in
PARP null vessels. This observation was supported by real-time monitoring of the accumula-
tion of BSA-647 in B16 tumors in dorsal window chambers, when treatment with rucaparib in
WT mice evoked impressive accumulation of fluorescence in tumors (1.85-fold increase in
fluorescence above initial baseline in WT, 0.97-fold in PARP-1-/-; p = 0.004—Fig. 4C), while
antagonism, the time taken for relaxation to complete was prolonged in all cases tested in tail artery. ***p<0.001 compared to time taken for relaxation
plateau in the absence of P2 antagonism. Panel D; representative trace of rucaparib-induced relaxation when the P2Y1 receptor was antagonised using
MRS-2179 (top), and rucaparib-induced relaxation (bottom). Bars represent mean of at least three independent experiments. Error bars represent SEM.
Arteries from at least three rats were used per test.
doi:10.1371/journal.pone.0118187.g003
Fig 4. Effects of rucaparib on tumor vessel perfusionmay be dependent on PARP. Panels A and B; B16 tumours were established in PARPWT or KO
female mice. The extent of vessel ‘mismatch’ following the administration of the perfusion markers Hoechst 33342 and carbocyanin was reduced by
rucaparib (1 mg/kg) in tumors established in WT but not PARP-1-/- mice. Panel C; fold change in intratumoral fluorescence above that seen following initial
plateau (20 min) in dorsal window chambers implanted with B16 tumors in WT and PARP-1-/- mice and treated with 1 mg/kg rucaparib. Panel D;
representative real time analysis of the accumulation of BSA-647 (administered via iv injection at time 0) in B16 tumors established in dorsal window
chambers in PARPWT (closed symbols) and PARP-1-/- (open symbols) mice. Arrow indicates the administration of rucaparib (10 mg/kg). NS—p>0.05,
*p<0.05, **p<0.01 as compared with relevant control. N = 3 mice per condition.
doi:10.1371/journal.pone.0118187.g004
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levels of BSA-647 following similar treatment in PARP-1-/- mice failed to increase above base-
line plateau (exemplar of one mouse from both groups can be seen in Fig. 4D).
Vasoactivity of rucaparib in human tumor-associated vessels
Previously, we investigated the vasoactivity of nicotinamide in vascular tissue isolated from pa-
tients post-nephrectomy for renal cell carcinoma [15], and found that nicotinamide blocked
both spontaneous and phenylephrine-induced contraction, although not all vessels were re-
sponsive. In this study, we aimed to determine the pattern of response to rucaparib in similar
tissues. In total, ten patients (all with renal cell carcinoma) consented to provide their tissue for
inclusion in this study. From these, nine full concentration-response curves were constructed
in tissues that were pre-constricted with 10 μM PE (Fig. 5A). There was heterogeneity of re-
sponse that did not seem to be dependent on the gender of the tissue donor. The tissue summa-
rised in panels B1 and B2 came from the tenth donor. Tissue section B1 was constricted with
PE as normal and treated with 100 μM rucaparib. Tissue in panel B2 was not constricted with
PE as the tissue contracted spontaneously in an oscillatory fashion; the data in panel B2 repre-
sents the effect of 100 μM rucaparib on the magnitude of these spontaneous oscillations
(Fig. 5B). The magnitude of responses of the tissues to PE are included in Table 1 to demon-
strate that lack of response to rucaparib was not a result of poor contractility of the tissues, and
also serves to demonstrate further heterogeneity in terms of degree of response of the tissues to
the α1 agonist itself.
Discussion
Vasoactive effects of PARP-1 inhibitors have been reported previously. In aging Fischer rats
that showed impaired vasorelaxation, treatment with the PARP inhibitor INO-1001 improved
maximal relaxation in response to acetylcholine [20], and PD128763 induced hypothermia (an
indicator of hypotension) in mice [21]. The latter was an ‘off target’ vasoactivity effect, as the
hypothermia following PD128763 treatment was observed in PARP-1-/- mice as well as PARP-
1+/+ mice. AG14361 provoked no such hypothermia in the same models [21].
It has been known for some time that the nicotinamide pharmacophore-containing PARP
inhibitors may inhibit other NAD+-dependent pathways. Indeed, the early benzamides inhib-
ited several metabolic pathways [22]. The more potent PARP-1 inhibitors in clinical develop-
ment are likely to be less promiscuous, although they do inhibit other PARP enzymes to
varying degrees. Indeed, rucaparib inhibits not only PARP-1, but also PARPs 2–4, and tankyr-
ase 1 [23]. Rucaparib was more potent an inhibitor of MLCK activity than nicotinamide [10],
and was ten times more potent than ML-9, (Fig. 1D), and was also a more potent vasodilator
than ML-9, a known vasodilator [24]. Hence, a role for MLCK inhibition in rucaparib-evoked
vasodilation is likely. Rucaparib and ML-9 were equipotent dilators in tail artery, while ruca-
parib was more potent than ML-9 in aorta, which could be due to differential expression or ac-
tivity of MLCK between the two tissues [25]. NO_ is a potent vasodilator (increases PKG
activity, in turn phosphorylating MLCK, deactivating it [26]) that has been implicated in
PARP inhibitor-mediated vasoactivity [27,28]. Although L-NMMA treatment did not signifi-
cantly affect rucaparib-evoked dilation, interaction of rucaparib with other targets could ac-
count for the persistence of dilation when NOS enzymes were inhibited.
While the apparent absence of vasoactivity in PARP-1-/- mice was curious (Fig. 4), the phe-
nomenon is not without precedent. Inhibition of PARP-1 with veliparib sensitized wild-type
murine embryonic fibroblasts to camptothecin, although PARP-1-/- counterparts were not sim-
ilarly sensitive, suggesting that PARP-1 inhibition and PARP-1 absence are not equivalent
[29]. Similarly, PARP inhibition with olaparib manifested DNA damage accumulation and cell
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cycle arrest in wild-type DT40 cells, but PARP-1-/- counterparts did not display these charac-
teristics, and olaparib sensitized wild-type cells to methyl methanesulfonate, sensitivity that
was lacking in PARP-1-/- [30]. In that respect, our vasodilation results are comparable with the
Fig 5. Heterogeneity of rucaparib activity in arteries isolated from patients having undergone nephrectomy. Panel A; concentration-response curves
that were generated. Tissues were constricted using 10 μMPE, before being treated with PE and the relevant concentration of rucaparib. Panels B1 and B2;
responses of two separate arterial sections from a single donor; panel B1 details the relaxant activity when a single tissue segment was constricted using
10 μMPE before being relaxed using 100 μM rucaparib; panel B2 details the slight inhibition of spontaneous oscillation of a single tissue segment that was
observed following treatment with 100 μM rucaparib (the tissue contracted spontaneously, so no PE constriction was performed). Points/bars in most cases
represent mean of two parallel experiments. Error bars represent SEM. Panels B1 and B2 error bars, as only a single observation was made per
tissue section.
doi:10.1371/journal.pone.0118187.g005
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above, where inhibited PARP and absence of PARP did not correlate. PARP-1-/- mice still re-
tain PARPs 2–4 (which rucaparib inhibits [23]), although these PARPs were unable to com-
pensate for PARP-1’s absence in PARP-1-/- mice. Veliparib [29], olaparib and niraparib [30],
BMN 673 and rucaparib [31] all trap PARP-1 at sites of DNA lesions, forming a putative toxic
protein product. A similar scenario may exist in vascular muscle contraction, when a complex
between rucaparib and PARP-1 is responsible for dilation, meaning rucaparib is impotent in
PARP-1’s absence.
Structural similarity to NAD+ led us to hypothesize that rucaparib might interact with a P2
receptor, known to be responsible for β-NAD-mediated inhibition of smooth muscle contrac-
tion [19]. We were unable to categorically identify P2 receptors involved in vasoactivity, al-
though P2X1, P2X2, P2Y1, P2Y2, P2Y4 and P2Y6 are all candidates [16]. Differential receptor
expression may explain rucaparib’s higher potency (55-times) in tail artery over aorta. It was
an interesting finding that P2 antagonism completely abolished rucaparib’s vasoactivity, as
MLCK inhibition could have been expected to compensate for the impact of P2 blockade.
NAD+ enters NAD+-deprived astrocytes through P2X7-gated channels [32]; it may be that a
similar mechanism of internalization exists for rucaparib, whereby MLCK inhibition-mediated
dilation is contingent upon P2X receptor-mediated internalization of the PARP-1 inhibitor.
The behaviour of human vascular tissue reported here is consistent with the behaviour of
similar tissue from our previous human vessel study [15]. Dilation of tumor-supplying vessels
should improve tumor oxygenation, thereby improving radiotherapy, or increase anticancer
drug delivery, as well as improving delivery of the PARP inhibitor itself to the tumor, with con-
sequent increased intra-tumoral PARP inhibition. Chemopotentiation of temozolomide by
rucaparib has already been reported, and was proposed to be resultant of vasoactivity of the
drug [11]. Pharmacokinetic data indicate that the Cmax of rucaparib at the chemosensitizing
dose of 12 mg/m2 was between 1.3 and 1.7 μM in patients [33]. As a single agent, oral rucaparib
(840 mg BID) resulted in steady state levels of around 9 μMwith trough levels 2 μM at doses
240 mg BID [34]. Vasoactivity of rucaparib was observed at 1 μM in both rat arterial tissues
and in six of the nine patient vessels for which concentration response curves were constructed,
suggesting that the phenomenon observed in vitro and in mice may have relevance in patients,
although, to our knowledge, this has not been determined.
Table 1. Summary of rucaparib activity in PE-constricted human tumor-associated vasculature.
Specimen Gender of donor Mean PE response (g) Mean rucaparib relaxation (g)
A1 Male 0.46 0.12
A2 Male 0.51 0.07
A3 Female 0.58 0.09
A4 Male 0.08 0.04
A5a Male 0.83 0.37
A6 Male 2.47 0.78
A7 Male 0.58 0.08
A8 Female 1.76 0.39
A9 Male 1.71 0.39
B1b Male 1.30 0.75
aData presented represents the magnitude of vessel relaxation in response to the top concentration of rucaparib tested, except A5, where the second
highest concentration is summarised.
bVessel section B1 was constricted with PE as the ‘A’ vessels; B2 contracted spontaneously, so is not summarized in Table 1.
doi:10.1371/journal.pone.0118187.t001
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If vasodilation is a common feature of PARP inhibitors containing the nicotinamide phar-
macophore, it would broaden the range of chemotherapeutics beyond temozolomide and the
topoisomerase I poisons that could be enhanced. Indeed, there are numerous clinical trials
combining PARP inhibitors with paclitaxel, carboplatin, and gemcitabine currently underway,
and the success of these trials may be more dependent on improved drug delivery rather than
inhibition of DNA repair. Rucaparib did not potentiate doxorubicin, although doxorubicin-as-
sociated cardiotoxicity was abrogated by the PARP-1 inhibitor [35]. The therapeutic benefits of
carboplatin and gemcitabine in patients with triple negative breast cancer were significantly en-
hanced by BSI-201 [36]; as BSI-201 has now been conclusively demonstrated to not inhibit
PARP [37], it is possible that its nicotinamide pharmacophore affords it vasoactivity-depen-
dent chemopotentiation. Olaparib also dilated constricted rat arteries ex vivo [38]. As olaparib
and BSI-201, like rucaparib, contain nicotinamide pharmacophores, these agents may exert va-
soactivity via a similar mechanism.
The current report provides tantalising evidence of the mechanisms underlying rucaparib-
mediated vasodilation. It was interesting to note that rucaparib was vasoactive in normal rat
tissue as well as tumor-recruited mouse and human vessels. Vasoactivity in the human tumor-
associated vessels was especially meaningful, as it translates preliminary lab-based findings to
clinically relevant material. Differential P2 receptor expression may explain the heterogeneity
of response we observed in patient material, and profiling patients may allow selection for max-
imum benefit from PARP inhibitor-cytotoxic combination therapy in the future.
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